What is the long-term trend for Johnson & Johnson's innovative medicine — restructuring (note 12)?

Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — restructuring (note 12) has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.

What does innovative medicine — restructuring (note 12) mean?

These are costs associated with organizational changes, facility closures, or workforce reductions specifically within the Innovative Medicine segment. It reflects management's efforts to optimize the cost structure and improve operational efficiency.

Johnson & Johnson (JNJ) Innovative Medicine — Restructuring (Note 12)

Screener

Other segment segments

Orthopaedics Restructuring Plan

$307M—

Medtech Ortho Franchise

$152M+15.2%

MEDTECH

$17M-66.0%

Similar metrics at other companies

GEFInnovative Closure Solutions — Restructuring Charges

$800K—

VLTOProduct Quality & Innovation — Restructuring Charges

$22M—

AMRXAffordable Medicines — Restructuring and other charges

$0-100%

CCKOther — Restructuring

$0-100%

ULSConsumer — Restructuring

-$1M0.0%

ULSIndustrial — Restructuring

$1M—

Other financials

Income statement

See full

Revenue$25.3B+6.6%

Gross profit$17.3B+7.1%

Operating income$7.1B+7.4%

Net income$5.5B-0.1%

EPS (diluted)$2.27-0.9%

Balance sheet

See full

Cash & equivalents$20.4B+9.9%

Total debt$49.0B-3.4%

Total equity$85.0B+8.3%

Total assets$201.06B+4.0%

Cash flow

See full

Operating cash flow$8.6B+122%

CapEx$1.3B+26.7%

Free cash flow$7.3B+157%

Valuation

See full

Market cap$620.77B+51.1%

Enterprise value$649.38B+46.6%

P/E29.5×+11.4×

P/S6.3×+1.8×

Profitability

See full

Gross margin67.9%0.0pp

Operating margin26.5%+2.8pp

Net margin21.5%-3.5pp

FCF margin22.7%+2.2pp

Returns & leverage

See full

Return on equity25.7%-4.5pp

Debt / equity0.6×-0.1×

Current ratio1.1×+0.1×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The source filing: Johnson & Johnson’s 10-Q, filed July 23, 2026.

Filed: Jul 23, 2026, 4:04 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000200406-26-000153

Restructuring related charge of $0.2 billion in both the fiscal second quarter and fiscal six months of 2026. Refer to Note 12 for additional details.
Acquisition and integration related expense of $0.1 billion in both the fiscal second quarter of 2026 and fiscal six months of 2026 and $0.2 billion in both the fiscal second quarter of 2025 and fiscal six months of 2025, primarily related to the Intra-Cellular acquisition.

Item 1 — Financial statements

FAQ

What is Johnson & Johnson's innovative medicine — restructuring (note 12)?: Johnson & Johnson (JNJ) reported innovative medicine — restructuring (note 12) of $200M in Q2 2026.
What is the long-term trend for Johnson & Johnson's innovative medicine — restructuring (note 12)?: Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — restructuring (note 12) has grown at a 0.0% compound annual growth rate (CAGR), from $100M to $100M.
What does innovative medicine — restructuring (note 12) mean?: These are costs associated with organizational changes, facility closures, or workforce reductions specifically within the Innovative Medicine segment. It reflects management's efforts to optimize the cost structure and improve operational efficiency.